Wall Street is wrapping up a volatile week — but certain stocks managed to outperform the remaining. The S & P 500 ended the week with a 1.43% gain, while the Nasdaq Composite added 4.4%. Meanwhile, the Dow Jones Industrial Average inched lower by 0.15%. These mixed results come amid investor anxieties on contagion of a banking sector crisis. Following the failures of Silicon Valley Bank and Signature Bank , financial stocks have taken a tough hit, particularly regional banks. Investors were further rattled by signs of instability at Credit Suisse and First Republic , driving down each shares 6.9%% and 32.8% on Friday, respectively. Using FactSet data, CNBC Pro screened for this week’s top gainers as of Friday morning, and what analysts expect for them going forward. Tech giant Microsoft was considered one of the most important S & P 500 winners this week, rallying 13.3% week thus far as of Friday morning. Microsoft shares are inside shouting distance of analysts’ average price goal for the subsequent 12 months, with upside of about 1%. Nearly 7 out 10 analysts covering the stock rate it a buy. Similarly, chipmakers Advanced Micro Devices and Nvidia outperformed this week but could also be getting ahead of themselves. AMD had the most important gains this week out of all S & P 500 stocks, up 17.8% week-to-date. AMD is on pace for its best week since 2020. Nevertheless, shares are already greater than 5% higher than their average price goal. Nvidia shares have also run ahead of their average price goal. Nevertheless, Morgan Stanley upgraded shares to chubby from equal weight on Thursday, citing artificial intelligence developments as tailwinds to growth. The firm raised its price goal on shares to $304 from $255, implying 19% upside from Thursday’s close. Meta and Alphabet shares also made the list of this week’s biggest gainers, rising 12% and 13%, respectively. Analysts anticipate Alphabet’s stock having 22.2% upside from here. UBS reiterated its buy rating for Alphabet shares , saying that it sees “cost risk around the mixing of generative AI into Google search results as manageable.” Illumina and Insulet were the 2 health-care firms that beat the market this week. Illumina shares jumped 15.3% week thus far as billionaire activist Carl Icahn prepared for a proxy fight at Illumina . Icahn is arguing the corporate cost its shareholders about $50 billion after pushing through its acquisition of GRAIL in August 2021. To be certain, analysts are mixed on Illumina, with only 34.8% analysts rating it a buy. Shares are estimated to achieve greater than 5% in the course of the next 12 months. —CNBC’s Michael Bloom contributed to this report.